Rivotril 2mg 100cts Clonazepam

Descripción Del Producto

Rivotril 2 mg oral tablets deliver clonazepam, an intermediate-onset, long-acting chlorinated nitrobenzodiazepine derivative, packaged in standardized 100-count amber glass or high-density polyethylene (HDPE) institutional dispensing bottles. Designed for controlled hospital, retail pharmacy, and institutional distribution, this formulation provides precise dose individualization for severe panic states and refractory epileptic disorders.

Clinical Profile & Physical Presentation

• Active Pharmaceutical Ingredient: Clonazepam (2 mg per tablet)

• Packaging Specification: 100-count sealed bottles with child-resistant safety closures and desiccant packs to protect against ambient moisture degradation.

• Physical Identification: Round, white-to-pale-yellow tablet with a cross-scoring line (quadrisect) debossed on one face (allowing division into equal 0.5 mg quadrants) and “ROCHE 2” or corresponding national marketing imprint on the reverse.

• Indications: Management of panic disorder, agoraphobia, status epilepticus stabilization, Lennox-Gastaut syndrome, and refractory myoclonic or akinetic seizures.

Pharmacodynamics & Mechanism of Action

• Receptor Complex Modulation: Selectively binds to the benzodiazepine allosteric regulatory site situated at the interface of $\alpha_1$, $\alpha_2$, $\alpha_3$, or $\alpha_5$ subunits with the $\gamma_2$ subunit on pentameric $\text{GABA}_\text{A}$ chloride channel complexes.

• Chloride Influx & Hyperpolarization: Increases channel opening frequency in the presence of endogenous gamma-aminobutyric acid ($\text{GABA}$), stimulating post-synaptic chloride ion influx. The resulting neuronal membrane hyperpolarization decreases spontaneous action potential generation across the motor cortex, hippocampal pathways, and the limbic system.

Pharmacokinetics & Metabolism

• Bioavailability & Onset: Demonstrates an absolute oral bioavailability of approximately 90%, reaching peak plasma concentrations ($C_{\max}$) within 1 to 4 hours post-administration.

• Half-Life & Distribution: Highly lipophilic with a large volume of distribution ($1.5–4.4 \text{ L/kg}$) and a protracted elimination half-life ranging from 30 to 40 hours, supporting steady plasma levels without frequent re-dosing.

• Hepatic Biotransformation: Extensively transformed via hepatic nitroreduction (primarily CYP3A4-mediated pathways) to 7-amino-clonazepam, an inactive metabolite, with less than 2% excreted unchanged in urine.

Important Safety Information & Boxed Warnings

• Concomitant Opioid Risk: Co-administration of benzodiazepines with opioids may result in profound sedation, life-threatening respiratory depression, coma, and death. Reserve combination prescribing solely for patients with inadequate alternative treatment options.

• Abuse, Misuse, and Addiction: Clonazepam is a Schedule IV controlled substance (Class C in the UK) with substantial liability for psychological and physiological dependence, misuse, and diversion.

• Dependence and Withdrawal: Prolonged continuous therapy results in physiological dependence. Abrupt discontinuation or rapid dosage reduction can precipitate severe, potentially fatal withdrawal reactions, including status epilepticus, extreme autonomic instability, hallucinations, and delirium tremens. Discontinuation mandates a gradual, medically monitored taper.

• Dispensing Governance: Storage in temperature-controlled environments ($15^\circ\text{C}$ to $25^\circ\text{C}$) inside a secure vault or locked dispensary fixture is required by law.